1 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005066)
|
2 |
US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases.
|
3 |
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
|
4 |
Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
|
5 |
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
|
6 |
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
|
7 |
Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
|
8 |
2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
|
9 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
|
10 |
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
|
11 |
2011 Pipeline of Boehringer Ingelheim Pharma.
|
12 |
2011 Pipeline of Bristol-Myers Squibb.
|
|
|
|
|
|
|